艾愈胶囊联合CAF化疗方案治疗乳腺癌的临床研究

Clinical study on Aiyu Capsules combined with CAF chemotherapy in treatment of breast cancer

目的探讨艾愈胶囊联合CAF化疗方案治疗乳腺癌患者的临床疗效。方法选取2013—2015年宜昌市第二人民医院收治的女性乳腺癌患者89例,随机分为对照组(44例)和治疗组(45例)。对照组静脉推注注射用盐酸多柔比星60 mg/m2,注射用环磷酰胺600 mg/m2,静脉滴注氟脲嘧啶注射液500 mg/m2,第1、8天各1次,21 d为1个疗程。治疗组在对照组的基础上口服艾愈胶囊,3粒/次,3次/d,21 d为1个疗程。两组均连续治疗2个疗程。观察两组的临床疗效,同时比较两组治疗前后血清血管内皮生长因子(VEGF)、CA125、CA153和癌胚抗原(CEA)水平及不良反应情况。结果治疗后,对照组总有效率和稳定率分别为34.09%和56.82%,分别低于治疗组的57.78%和77.78%,两组比较差异有统计学意义(P<0.05)。治疗后,两组血清VEGF、CA125、CA153和CEA水平均有一定程度降低,与治疗前相比差异有统计学意义(P<0.05)。且治疗组上述指标水平显著低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗期间,对照组患者白细胞和血红蛋白减少发生率高于治疗组,两组比较差异具有统计学意义(P<0.05)。结论艾愈胶囊联合CAF化疗方案可以更好控制乳腺癌患者的VEGF以及相关肿瘤标志物水平,取得更好治疗效果,具有一定的临床推广应用价值。

Objective To observe the clinical effect of Aiyu Capsules combined with CAF chemotherapy in treatment of breast cancer. Methods Female patients （89 cases） with breast cancer in the Second People＇s Hospital of Yichang from 2013 to 2015 were randomly divided into control （44 cases） and treatment （45 cases） groups. The patients in the control group were iv administered with Doxorubicin Hydrochloride for injection 60 mg/m2 and Cyclophosphamide for injection 600 mg/m2, and were iv administered with Fluorouracil Injection 500 mg/m2, each time at the first and eighth day, 21 d for a course of treatment, in the treatment group were po administered with Aiyu Capsules on the basis of the control group, 3 grains/time, three times daily, 14 d for a course of treatment. The patients in two groups were treated for two courses of treatment. After treatment, the efficacy was observed, and the levels of VEGF, CA125, CA153, and CEA, and adverse reactions in two groups were compared. Results After treatment, the total efficacies and stable rate in the control group were 34.09% and 56.82%, respectively, and which were significantly lower than those （57.78% and 77.78%） in the treatment group, and there were differences between two groups （P 〈 0.05）. After treatment, the levels of VEGF, CA125, CA153, and CEA in two groups were significantly decreased, and the difference was statistically significant in the same group （P 〈 0.05）. And these observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups （P 〈 0.05）. During the treatment, white blood cell and hemoglobin decrease rate in the control group were significantly higher than those in the treatment group, and there were differences between two groups （P 〈 0.05）. Conclusion Aiyu Capsules combined with CAF chemotherapy can control VEGF and the related tumor markers of patients with breast cancer, achieve a better therapeutic effect, and which has a certain clinical application value.